Simtuzumab, an Antifibrotic Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) Enzyme, Is Safe and Well Tolerated in Patients With Liver Disease
|
|
| Reported by Jules Levin
EASL 2013 April Amsterdam
Andrew H. Talal1,2, Marlene Feron-Rigodon1, Jeannine Madere3, Xiaoru Wu3, G. Mani Subramanian3, Jeffrey D. Bornstein31Weill-Cornell Medical College, New York, NY, USA; 2SUNY-Buffalo, Buffalo, NY, USA; 3Gilead Sciences, Inc., Foster City, CA, USA 
|
|
|  | |
|
|